117 related articles for article (PubMed ID: 38457748)
1. Using Tumor Marker Gene Variants to Improve the Diagnostic Accuracy of DUPAN-2 and Carbohydrate Antigen 19-9 for Pancreatic Cancer.
Ando Y; Dbouk M; Yoshida T; Saba H; Abou Diwan E; Yoshida K; Dbouk A; Blackford AL; Lin MT; Lennon AM; Burkhart RA; He J; Sokoll L; Eshleman JR; Canto MI; Goggins M
J Clin Oncol; 2024 Jun; 42(18):2196-2206. PubMed ID: 38457748
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic Performance of a Tumor Marker Gene Test to Personalize Serum CA19-9 Reference Ranges.
Dbouk M; Abe T; Koi C; Ando Y; Saba H; Abou Diwan E; MacGregor-Das A; Blackford AL; Mocci E; Beierl K; Dbouk A; He J; Burkhart R; Lennon AM; Sokoll L; Canto MI; Eshleman JR; Goggins M
Clin Cancer Res; 2023 Oct; 29(20):4178-4185. PubMed ID: 37566230
[TBL] [Abstract][Full Text] [Related]
3. Using a CA19-9 Tumor Marker Gene Test to Assess Outcome After Pancreatic Cancer Surgery.
Ando Y; Dbouk M; Blackford AL; Yoshida T; Saba H; Abou Diwan E; Yoshida K; Sokoll L; Eshleman JR; Burkhart R; He J; Goggins M
Ann Surg Oncol; 2024 May; 31(5):2902-2912. PubMed ID: 38319515
[TBL] [Abstract][Full Text] [Related]
4. Gene Variants That Affect Levels of Circulating Tumor Markers Increase Identification of Patients With Pancreatic Cancer.
Abe T; Koi C; Kohi S; Song KB; Tamura K; Macgregor-Das A; Kitaoka N; Chuidian M; Ford M; Dbouk M; Borges M; He J; Burkhart R; Wolfgang CL; Klein AP; Eshleman JR; Hruban RH; Canto MI; Goggins M
Clin Gastroenterol Hepatol; 2020 May; 18(5):1161-1169.e5. PubMed ID: 31676359
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma.
Kondo N; Murakami Y; Uemura K; Nakagawa N; Takahashi S; Ohge H; Sueda T
Pancreatology; 2017; 17(1):95-102. PubMed ID: 27746094
[TBL] [Abstract][Full Text] [Related]
6. FUT2 and FUT3 genotype determines CA19-9 cut-off values for detection of cholangiocarcinoma in patients with primary sclerosing cholangitis.
Wannhoff A; Hov JR; Folseraas T; Rupp C; Friedrich K; Anmarkrud JA; Weiss KH; Sauer P; Schirmacher P; Boberg KM; Stremmel W; Karlsen TH; Gotthardt DN
J Hepatol; 2013 Dec; 59(6):1278-84. PubMed ID: 23958938
[TBL] [Abstract][Full Text] [Related]
7. Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer.
Dong D; Jia L; Zhang L; Ma N; Zhang A; Zhou Y; Ren L
Cancer Sci; 2018 Sep; 109(9):2841-2851. PubMed ID: 29945294
[TBL] [Abstract][Full Text] [Related]
8. Serum Carboxypeptidase Activity and Genotype-Stratified CA19-9 to Detect Early-Stage Pancreatic Cancer.
Tanaka H; Tamura K; Abe T; Yoshida T; Macgregor-Das A; Dbouk M; Blackford AL; Borges M; Lennon AM; He J; Burkhart R; Canto MI; Goggins M
Clin Gastroenterol Hepatol; 2022 Oct; 20(10):2267-2275.e2. PubMed ID: 34648951
[TBL] [Abstract][Full Text] [Related]
9. Clinical Utility of the Combined Use of CA19-9 and DUPAN-2 in Pancreatic Adenocarcinoma.
Sumiyoshi T; Uemura K; Shintakuya R; Okada K; Baba K; Harada T; Serikawa M; Ishii Y; Nakamura S; Arihiro K; Murakami Y; Takahashi S
Ann Surg Oncol; 2024 Jul; 31(7):4665-4672. PubMed ID: 38652196
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of serum carbohydrate antigen 19.9 and duke pancreatic monoclonal antigen type 2 for the prediction of hematogenous metastases in patients with pancreatic ducal adenocarcinoma.
Kurahara H; Maemura K; Mataki Y; Sakoda M; Iino S; Arigami T; Mori S; Ueno S; Shinchi H; Takao S; Natsugoe S
Pancreatology; 2016; 16(6):1051-1056. PubMed ID: 27693096
[TBL] [Abstract][Full Text] [Related]
11. Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9.
Makawita S; Dimitromanolakis A; Soosaipillai A; Soleas I; Chan A; Gallinger S; Haun RS; Blasutig IM; Diamandis EP
BMC Cancer; 2013 Sep; 13():404. PubMed ID: 24007603
[TBL] [Abstract][Full Text] [Related]
12. Inflammation But Not Biliary Obstruction Is Associated With Carbohydrate Antigen 19-9 Levels in Patients With Primary Sclerosing Cholangitis.
Wannhoff A; Rupp C; Friedrich K; Brune M; Knierim J; Flechtenmacher C; Sauer P; Stremmel W; Hov JR; Schirmacher P; Weiss KH; Gotthardt DN
Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2372-9. PubMed ID: 26192140
[TBL] [Abstract][Full Text] [Related]
13. Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer.
Capello M; Bantis LE; Scelo G; Zhao Y; Li P; Dhillon DS; Patel NJ; Kundnani DL; Wang H; Abbruzzese JL; Maitra A; Tempero MA; Brand R; Firpo MA; Mulvihill SJ; Katz MH; Brennan P; Feng Z; Taguchi A; Hanash SM
J Natl Cancer Inst; 2017 Apr; 109(4):. PubMed ID: 28376157
[TBL] [Abstract][Full Text] [Related]
14. The sTRA Plasma Biomarker: Blinded Validation of Improved Accuracy Over CA19-9 in Pancreatic Cancer Diagnosis.
Staal B; Liu Y; Barnett D; Hsueh P; He Z; Gao C; Partyka K; Hurd MW; Singhi AD; Drake RR; Huang Y; Maitra A; Brand RE; Haab BB
Clin Cancer Res; 2019 May; 25(9):2745-2754. PubMed ID: 30617132
[TBL] [Abstract][Full Text] [Related]
15. Plasma miRNA Biomarkers in Limited Volume Samples for Detection of Early-stage Pancreatic Cancer.
Dittmar RL; Liu S; Tai MC; Rajapakshe K; Huang Y; Longton G; DeCapite C; Hurd MW; Paris PL; Kirkwood KS; Coarfa C; Maitra A; Brand RE; Killary AM; Sen S
Cancer Prev Res (Phila); 2021 Jul; 14(7):729-740. PubMed ID: 33893071
[TBL] [Abstract][Full Text] [Related]
16. Increased levels of both carbohydrate antigen 19-9 and duke pancreatic monoclonal antigen type 2 reflect postoperative prognosis in patients with pancreatic carcinoma.
Shibata K; Iwaki K; Kai S; Ohta M; Kitano S
Pancreas; 2009 Aug; 38(6):619-24. PubMed ID: 19436235
[TBL] [Abstract][Full Text] [Related]
17. New observations on the utility of CA19-9 as a biomarker in Lewis negative patients with pancreatic cancer.
Luo G; Fan Z; Cheng H; Jin K; Guo M; Lu Y; Yang C; Fan K; Huang Q; Long J; Liu L; Xu J; Lu R; Ni Q; Warshaw AL; Liu C; Yu X
Pancreatology; 2018 Dec; 18(8):971-976. PubMed ID: 30131287
[TBL] [Abstract][Full Text] [Related]
18. Utility of serum CA19-9 levels in the diagnosis of pancreatic ductal adenocarcinoma in an endoscopic ultrasound referral population.
Parikh DA; Durbin-Johnson B; Urayama S
J Gastrointest Cancer; 2014 Mar; 45(1):74-9. PubMed ID: 24272911
[TBL] [Abstract][Full Text] [Related]
19. Identification of Serum Biomarker Panels for the Early Detection of Pancreatic Cancer.
Song J; Sokoll LJ; Pasay JJ; Rubin AL; Li H; Bach DM; Chan DW; Zhang Z
Cancer Epidemiol Biomarkers Prev; 2019 Jan; 28(1):174-182. PubMed ID: 30333219
[TBL] [Abstract][Full Text] [Related]
20. Comparison of circulating MMP-9, TIMP-1 and CA19-9 in the detection of pancreatic cancer.
Joergensen MT; Brünner N; De Muckadell OB
Anticancer Res; 2010 Feb; 30(2):587-92. PubMed ID: 20332475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
